-
STUDY17022
First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Study Information
-
STUDY17262
Combination of Autophagy Selective Therapeutics (COAST) in Relapsed Gynecological Cancers, Relapsed Prostate Cancer, or other Advanced Solid Tumors, a Phase I/II Trial
Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy.
Study Information
-
STUDY22550
Phase 1 Dose Escalation Study for a Trispecific Antibody (SAIL66), Targeting Solid Tumors Expressing CLDN-6 and CD3/CD137+ T-cells
Incidence, nature, and severity of adverse events graded according to NCI Common Terminology CTCAE v5.0, with severity of CRS and ICANS determined according to the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Criteria. Incidence, nature, and severity of adverse events graded according to NCI CTCAE v5.0, with severity of CRS and ICANS determined according to the ASTCT Consensus Grading Criteria.
Study Information
-
STUDY22631
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
Among patients with metastatic extrapulmonary poorly differentiated small cell NEC, to compare overall survival (OS, measured from randomization) in a fixed sequence as follows:
a. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus induction platinum/etoposide alone (Arm 3)
b. Compare the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2) versus induction platinum/etoposide alone (Arm 3)
c. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2)
Study Information
-
STUDY23589
A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC and HNSCC. To characterize the safety and tolerability
of ABBV-400 as monotherapy in advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC, and HNSCC.
Study Information